Format

Send to

Choose Destination
J Endocrinol Invest. 2019 Feb;42(2):199-205. doi: 10.1007/s40618-018-0903-3. Epub 2018 May 23.

Increased serum interleukin-37 (IL-37) levels correlate with oxidative stress parameters in Hashimoto's thyroiditis.

Author information

1
Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. rmruggeri@unime.it.
2
UOC di Endocrinologia, Dipartimento di Medicina Clinica e Sperimentale, Padiglione H, 4 piano - Policlinico Universitario "G. Martino", 98125, Messina, Italy. rmruggeri@unime.it.
3
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
4
Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
5
Unit of Statistical and Mathematical Sciences, Department of Economics, University of Messina, Messina, Italy.
6
Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences, and Morpho-Functional Images, University of Messina, Messina, Italy.
7
Accademia Peloritana dei Pericolanti, University of Messina, Messina, Italy.
8
Department of Clinical and Experimental Medicine, Postgraduate School and Division of Allergy and Clinical Immunology, University of Messina, Messina, Italy.

Abstract

PURPOSE:

Interleukin-37 (IL-37), member of the IL-1 family, is a natural suppressor of immune and inflammatory responses. Increased serum IL-37 levels were observed in several autoimmune diseases, including Graves' disease. To our knowledge, no data on Hashimoto's thyroiditis (HT) are available in the literature.

METHODS:

Aim of our study was to measure serum IL-37 levels and evaluate their relationship, if any, with oxidative stress markers in HT patients. We enrolled 45 euthyroid HT patients (5 M e 40 F, median age 40 years) and 50 age- and sex-matched healthy controls. None was under L-thyroxine therapy. Serum IL-37 levels were measured by ELISA. Specific serum tests, such as derived reactive oxygen metabolites (d-ROMs), and biological anti-oxidant potential (BAP) test were performed in all subjects to investigate the changes in oxidative balance, and advanced glycation end products (AGEs) were determined as a specific marker of oxidative stress.

RESULTS:

IL-37 levels were significantly higher in HT than in controls (median 475 vs. 268 pg/ml, P = 0.018). In the same patients, serum oxidants (d-ROMs) were increased and anti-oxidants (BAP) decreased compared with controls (P = 0.011 and < 0.0001, respectively), clearly indicating an enhanced oxidative stress. In addition, AGEs levels were higher in HT patients than in controls (210 vs. 140 AU/g prot, P < 0.0001) and directly correlated with IL-37 levels (P = 0.048). At multivariate analysis, the main independent predictors that influenced IL-37 levels were both anti-thyroid antibodies (P = 0.026) and AGEs levels (P = 0.001).

CONCLUSIONS:

IL-37 is up-regulated in HT and may exert a protective role by counteracting oxidative stress and inflammation.

KEYWORDS:

Advanced glycation end products (AGEs); Autoimmunity; Hashimoto’s thyroiditis; Interleukin-37; Oxidative stress

PMID:
29796799
DOI:
10.1007/s40618-018-0903-3

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center